CN112480235A - 一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 - Google Patents
一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 Download PDFInfo
- Publication number
- CN112480235A CN112480235A CN202011468803.1A CN202011468803A CN112480235A CN 112480235 A CN112480235 A CN 112480235A CN 202011468803 A CN202011468803 A CN 202011468803A CN 112480235 A CN112480235 A CN 112480235A
- Authority
- CN
- China
- Prior art keywords
- sgsaawddsaggaggqglrvtal
- gly
- ala
- peptide
- bioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 109
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 210000002540 macrophage Anatomy 0.000 claims abstract description 21
- 210000004027 cell Anatomy 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 11
- 230000007365 immunoregulation Effects 0.000 claims abstract description 9
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 230000001737 promoting effect Effects 0.000 claims abstract description 8
- 230000004913 activation Effects 0.000 claims abstract description 7
- 238000000338 in vitro Methods 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 18
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 230000002519 immonomodulatory effect Effects 0.000 claims description 7
- 230000004957 immunoregulator effect Effects 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 4
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000006315 carbonylation Effects 0.000 claims description 2
- 238000005810 carbonylation reaction Methods 0.000 claims description 2
- 230000021523 carboxylation Effects 0.000 claims description 2
- 238000006473 carboxylation reaction Methods 0.000 claims description 2
- 230000032050 esterification Effects 0.000 claims description 2
- 238000005886 esterification reaction Methods 0.000 claims description 2
- 230000013595 glycosylation Effects 0.000 claims description 2
- 238000006206 glycosylation reaction Methods 0.000 claims description 2
- 230000033444 hydroxylation Effects 0.000 claims description 2
- 238000005805 hydroxylation reaction Methods 0.000 claims description 2
- 230000011987 methylation Effects 0.000 claims description 2
- 238000007069 methylation reaction Methods 0.000 claims description 2
- 230000026731 phosphorylation Effects 0.000 claims description 2
- 238000006366 phosphorylation reaction Methods 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 230000008975 immunomodulatory function Effects 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 24
- 108090000623 proteins and genes Proteins 0.000 abstract description 24
- 230000006870 function Effects 0.000 abstract description 19
- 238000002474 experimental method Methods 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 244000052769 pathogen Species 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 230000003832 immune regulation Effects 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 23
- 239000011347 resin Substances 0.000 description 21
- 229920005989 resin Polymers 0.000 description 21
- 150000001413 amino acids Chemical group 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010077544 Chromatin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000003483 chromatin Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003226 decolorizating effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- USSYUMHVHQSYNA-SLDJZXPVSA-N indolicidin Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)CC1=CNC2=CC=CC=C12 USSYUMHVHQSYNA-SLDJZXPVSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ZQOILFFBJUNGRA-NMVUUJPQSA-N (4s)-4-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-[(2s)-2-[[(2s,3s)-1-[(2s)-2-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]pyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C ZQOILFFBJUNGRA-NMVUUJPQSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- KQFRUSHJPKXBMB-BHDSKKPTSA-N Ala-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C)C(O)=O)=CNC2=C1 KQFRUSHJPKXBMB-BHDSKKPTSA-N 0.000 description 1
- JAMAWBXXKFGFGX-KZVJFYERSA-N Ala-Arg-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JAMAWBXXKFGFGX-KZVJFYERSA-N 0.000 description 1
- YSMPVONNIWLJML-FXQIFTODSA-N Ala-Asp-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(O)=O YSMPVONNIWLJML-FXQIFTODSA-N 0.000 description 1
- FUSPCLTUKXQREV-ACZMJKKPSA-N Ala-Glu-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O FUSPCLTUKXQREV-ACZMJKKPSA-N 0.000 description 1
- BGNLUHXLSAQYRQ-FXQIFTODSA-N Ala-Glu-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BGNLUHXLSAQYRQ-FXQIFTODSA-N 0.000 description 1
- WGDNWOMKBUXFHR-BQBZGAKWSA-N Ala-Gly-Arg Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N WGDNWOMKBUXFHR-BQBZGAKWSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- UWIQWPWWZUHBAO-ZLIFDBKOSA-N Ala-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)N)CC(C)C)C(O)=O)=CNC2=C1 UWIQWPWWZUHBAO-ZLIFDBKOSA-N 0.000 description 1
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- QIWYWCYNUMJBTC-CIUDSAMLSA-N Arg-Cys-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QIWYWCYNUMJBTC-CIUDSAMLSA-N 0.000 description 1
- YBZMTKUDWXZLIX-UWVGGRQHSA-N Arg-Leu-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YBZMTKUDWXZLIX-UWVGGRQHSA-N 0.000 description 1
- GSUFZRURORXYTM-STQMWFEESA-N Arg-Phe-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 GSUFZRURORXYTM-STQMWFEESA-N 0.000 description 1
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 1
- QXHVOUSPVAWEMX-ZLUOBGJFSA-N Asp-Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXHVOUSPVAWEMX-ZLUOBGJFSA-N 0.000 description 1
- CUQDCPXNZPDYFQ-ZLUOBGJFSA-N Asp-Ser-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O CUQDCPXNZPDYFQ-ZLUOBGJFSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 1
- DSPQRJXOIXHOHK-WDSKDSINSA-N Glu-Asp-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O DSPQRJXOIXHOHK-WDSKDSINSA-N 0.000 description 1
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 1
- CGOHAEBMDSEKFB-FXQIFTODSA-N Glu-Glu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O CGOHAEBMDSEKFB-FXQIFTODSA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
- XPJBQTCXPJNIFE-ZETCQYMHSA-N Gly-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)CN XPJBQTCXPJNIFE-ZETCQYMHSA-N 0.000 description 1
- BUEFQXUHTUZXHR-LURJTMIESA-N Gly-Gly-Pro zwitterion Chemical compound NCC(=O)NCC(=O)N1CCC[C@H]1C(O)=O BUEFQXUHTUZXHR-LURJTMIESA-N 0.000 description 1
- QSVMIMFAAZPCAQ-PMVVWTBXSA-N Gly-His-Thr Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QSVMIMFAAZPCAQ-PMVVWTBXSA-N 0.000 description 1
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000209499 Lemna Species 0.000 description 1
- WQWSMEOYXJTFRU-GUBZILKMSA-N Leu-Glu-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O WQWSMEOYXJTFRU-GUBZILKMSA-N 0.000 description 1
- PBGDOSARRIJMEV-DLOVCJGASA-N Leu-His-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(O)=O PBGDOSARRIJMEV-DLOVCJGASA-N 0.000 description 1
- FOBUGKUBUJOWAD-IHPCNDPISA-N Leu-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FOBUGKUBUJOWAD-IHPCNDPISA-N 0.000 description 1
- IZPVWNSAVUQBGP-CIUDSAMLSA-N Leu-Ser-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IZPVWNSAVUQBGP-CIUDSAMLSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- QEVRUYFHWJJUHZ-DCAQKATOSA-N Met-Ala-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C QEVRUYFHWJJUHZ-DCAQKATOSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 1
- SSSFPISOZOLQNP-GUBZILKMSA-N Pro-Arg-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSFPISOZOLQNP-GUBZILKMSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 1
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 1
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- STTVVMWQKDOKAM-YESZJQIVSA-N Tyr-His-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O STTVVMWQKDOKAM-YESZJQIVSA-N 0.000 description 1
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 description 1
- LKUDRJSNRWVGMS-QSFUFRPTSA-N Val-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N LKUDRJSNRWVGMS-QSFUFRPTSA-N 0.000 description 1
- BZOSBRIDWSSTFN-AVGNSLFASA-N Val-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](C(C)C)N BZOSBRIDWSSTFN-AVGNSLFASA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010038633 aspartylglutamate Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010042598 glutamyl-aspartyl-glycine Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010079413 glycyl-prolyl-glutamic acid Proteins 0.000 description 1
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000021244 human milk protein Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 235000019239 indanthrene blue RS Nutrition 0.000 description 1
- UHOKSCJSTAHBSO-UHFFFAOYSA-N indanthrone blue Chemical compound C1=CC=C2C(=O)C3=CC=C4NC5=C6C(=O)C7=CC=CC=C7C(=O)C6=CC=C5NC4=C3C(=O)C2=C1 UHOKSCJSTAHBSO-UHFFFAOYSA-N 0.000 description 1
- 108010057821 leucylproline Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- YYVGYULIMDRZMJ-UHFFFAOYSA-N propan-2-ylsilane Chemical compound CC(C)[SiH3] YYVGYULIMDRZMJ-UHFFFAOYSA-N 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 108010030651 valyl-glutamyl-prolyl-isoleucyl-prolyl-tyrosine Proteins 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及蛋白领域,具体涉及一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL及其制备方法和应用,生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的氨基酸序列为Ser‑Gly‑Ser‑Ala‑Ala‑Trp‑Asp‑Asp‑Ser‑Ala‑Gly‑Gly‑Ala‑Gly‑Gly‑Gln‑Gly‑Leu‑Arg‑Val‑Thr‑Ala‑Leu。经过体外免疫调节功能实验,发现生物活性肽SGSAAWDDSAGGAGGQGLRVTAL具有较好的免疫调节功能。本发明的生物活性肽SGSAAWDDSAGGAGGQGLRVTAL可促进巨噬细胞活化并释放细胞因子,提高机体抵御外界病原体感染的能力,在有炎症发生的情况下对体外巨噬细胞吞噬中性红能力具有显著的促进作用,可降低机体发病率,提高生命的质量,对开发具有免疫调节功能的食品、保健品和药物具有十分重要的意义。
Description
技术领域
本发明涉及蛋白领域,尤其是涉及一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL及其制备方法和应用。
背景技术
近年来,生物活性肽已经成为人们耳熟能详的一个词语。因其具有很多潜在的生物功能,所以引起人们越来越多的关注,成为科学研究的热点之一。目前很多生物活性肽的有益效果也已经得到了很好的证明,如抗癌、降血压、抗菌、降胆固醇、抗糖尿病等等特性。当前最权威的生物活性肽数据库BIOPEP-UMW中已报告了3000多个不同的生物活性肽。
目前对于生物活性肽的研究多集中于食物衍生多肽,对非食物衍生多肽研究和报道较少。且已经有研究结果证实,与食物衍生的生物活性肽相比,非食物衍生的生物活性肽具有更高的亲和力并能有效发挥其生物活性功能。淋巴细胞是免疫系统的中央调节细胞,其大部分功能是由一组被称为淋巴因子的小分子多肽介导的。这些小分子多肽的表达和分泌均是由于抗原刺激的细胞激活而诱导。所以淋巴细胞是动物机体内产生免疫调节肽的主要来源。
免疫调节肽是继阿片肽发现后首次从乳中获得并证明其生理活性的一类生物活性肽。1981年Jolles等人首次发现,利用胰蛋白酶水解人乳蛋白,可以得到一个氨基酸序列为Val-Glu-Pro-Ile-Pro-Tyr的六肽,体外实验证明该肽能够增强小鼠腹腔巨噬细胞对绵羊红细胞的吞噬作用。Migliore-Samour等人发现来自酪蛋白的六肽Thr-Thr-Met-Pro-Leu-Trp能够刺激绵羊血红细胞对小鼠腹膜巨噬细胞的吞噬作用以及增强对于肺炎克雷伯菌的抵抗,具有抗炎功能。李素萍等人用合成的小鼠骨髓巨噬细胞来与源肽(PGPIPN)饲喂大鼠发现大鼠腹腔巨噬细胞的吞噬作用和红细胞相关的抗炎功能有显著的增强。Bowdis等人在研究来源于牛中性粒细胞的13氨基酸肽indolicidin的免疫功能时发现,多肽indolicidin在巨噬细胞样细胞系中抑制LPS诱导的TNF-α产量。
研究表明,免疫调节肽不仅能够增强机体免疫力,刺激机体淋巴细胞的增殖,增强巨噬细胞的吞噬功能,促进细胞因子的释放、促进巨噬细胞一氧化氮诱生量的增加、提高机体抵御外界病原体感染的能力,降低机体发病率,而且不会引起机体的免疫排斥反应。
免疫调节肽一般是指具有免疫调节活性的分子量相对较小的小肽。现在公开的免疫调节肽一般是从蛋白质中酶解分离得到或化学方法合成得到的具有特定免疫调节活性的小肽。但是当这些小肽未从蛋白质中酶解分离时,这些蛋白质本身往往是不具备免疫调节活性的。如何从已知氨基酸序列的种类繁多的蛋白质中寻找具有特定功能的生物活性肽,并研究这些多肽的功能是蛋白领域研究的方向之一。
Protein tyrosine phosphatase receptor type C-associated蛋白的氨基酸序列如SEQ ID NO:2所示。目前,现有技术中并没有关于Protein tyrosine phosphatasereceptor type C-associated蛋白多肽片段相关功能的研究。
发明内容
本发明的目的在于提供一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL及其制备方法和应用。
本发明的目的可以通过以下技术方案来实现:
本发明第一方面,提供一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL,其氨基酸序列为Ser-Gly-Ser-Ala-Ala-Trp-Asp-Asp-Ser-Ala-Gly-Gly-Ala-Gly-Gly-Gln-Gly-Leu-Arg-Va l-Thr-Ala-Leu,如SEQ ID NO:1所示。
较优的,所述生物活性肽为小鼠脾脏来源淋巴细胞肽。具体均来源于Proteintyrosine phosphatase receptor type C-associated蛋白,并且为Protein tyrosinephosphatase receptor type C-associated蛋白第175~197位的氨基酸残基。Proteintyrosine phosphatase receptor type C-associated蛋白氨基酸序列如SEQ ID NO:2所示。
Protein tyrosine phosphatase receptor type C-associated蛋白的氨基酸序列以及对应的核苷酸序列为既有技术,编码Protein tyrosine phosphatase receptortype C-associated蛋白第175~197位氨基酸残基的核苷酸片段能编码成熟的生物活性肽SGSAAWDDSAGGAGGQGLRVTAL。
较优的,所述生物活性肽具有抗炎功能和免疫调节功能。
本发明还提供编码所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的多核苷酸。
本发明第二方面,提供了所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的制备方法,可以通过基因工程的方法人工合成,可以从细胞中通过分离纯化的方法直接获得,可以直接通过化学合成制备。
通过基因工程的方法人工合成所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL是本领域技术人员能够实现的技术方案,例如可以是以DNA重组技术为基础,通过合适的DNA模板来控制多肽的序列合成。
关于从细胞中通过分离纯化的方法直接获得的方式可以为:基于给定的生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的氨基酸序列,采用生物学技术上常规的酶解、纯化方法从小鼠脾脏来源淋巴细胞获得所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL。
本发明第三方面,提供了所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备具有抗炎功能的药物或化妆品中的应用。
进一步地,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备有炎症发生的情况下对体外巨噬细胞吞噬中性红能力促进的药物中的应用。
本发明第四方面,提供了所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备具有免疫调节功能的食物或药物中的应用。
进一步地,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备促进巨噬细胞活化并释放细胞因子的食物或药物中的应用。
本发明第五方面,提供了一种具有免疫调节功能的产品,包括所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL或所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物;所述具有免疫调节功能的产品包括具有免疫调节功能的食品或具有免疫调节功能的药物;所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物是指具有与所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL相同的活性或更优的活性。
本发明第六方面,提供了一种抗炎产品,包括所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL或所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物;所述的抗炎产品包括抗炎药物或抗炎化妆品。所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物是指具有与所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL相同的活性或更优的活性。
所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物,是指在生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的氨基酸侧链基团上、氨基端或羧基端进行羟基化、羧基化、羰基化、甲基化、乙酰化、磷酸化、酯化或糖基化等修饰,得到的生物活性肽衍生物。
本发明生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的有益效果为:本发明生物活性肽SGSAAWDDSAGGAGGQGLRVTAL具有较好的抗炎活性;本发明的生物活性肽SGSAAWDDSAGGAGGQGLRVTAL可促进巨噬细胞活化并释放细胞因子,提高机体抵御外界病原体感染的能力,在有炎症发生的情况下对体外巨噬细胞吞噬中性红能力具有显著的促进作用,可降低机体发病率,提高生命的质量,对开发具有免疫调节功能的食品、保健品和药物具有十分重要的意义。
附图说明
图1:质荷比为1052.512的片段的一级质谱图(m/z=1052.512);
图2:质荷比为1052.512的片段的二级质谱图和生物活性肽az、by断裂情况;
具体实施方式
在进一步描述本发明具体实施方案之前,应理解,本发明的保护范围不局限于下述特定的具体实施方案;还应当理解,本发明实施例中使用的术语是为了描述特定的具体实施方案,而不是为了限制本发明的保护范围。
当实施例给出数值范围时,应理解,除非本发明另有说明,每个数值范围的两个端点以及两个端点之间任何一个数值均可选用。除非另外定义,本发明中使用的所有技术和科学术语与本技术领域技术人员通常理解的意义相同。除实施例中使用的具体方法、设备、材料外,根据本技术领域的技术人员对现有技术的掌握及本发明的记载,还可以使用与本发明实施例中所述的方法、设备、材料相似或等同的现有技术的任何方法、设备和材料来实现本发明。
除非另外说明,本发明中所公开的实验方法、检测方法、制备方法均采用本技术领域常规的分子生物学、生物化学、染色质结构和分析、分析化学、细胞培养、重组DNA技术及相关领域的常规技术。这些技术在现有文献中已有完善说明,具体可参见Sambrook等MOLECULAR CLONING:A LABORATORY MANUAL,Second edition,Cold Spring HarborLaboratory Press,1989and Third edition,2001;Ausubel等,CURRENT PROTOCOLS INMOLECULAR BIOLOGY,John Wiley&Sons,New York,1987and periodic updates;theseries METHODS IN ENZYMOLOGY,Academic Press,San Diego;Wolffe,CHROMATINSTRUCTURE AND FUNCTION,Third edition,Academic Press,San Diego,1998;METHODS INENZYMOLOGY,Vol.304,Chromatin(P.M.Wassarman and A.P.Wolffe,eds.),AcademicPress,San Diego,1999;和METHODS IN MOLECULAR BIOLOGY,Vol.119,ChromatinProtocols(P.B.Becker,ed.)Humana Press,Totowa,1999等。
下面结合附图和具体实施例对本发明进行详细说明。
实施例1生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的人工合成
一、生物活性肽的合成
1.称取RINK树脂3g(取代度0.3mmol/g)于150ml的反应器中,用50ml的二氯甲烷(DCM)浸泡。
2.2小时后,用3倍树脂体积的氮-二甲基甲酰胺(DMF)洗涤树脂,然后抽干,如此重复四次,将树脂抽干后待用。
3.向反应器中加入一定量的20%哌啶(哌啶/DMF=1:4,v:v),放在脱色摇床上摇晃20min,以此来脱去树脂上的Fmoc保护基团。脱完保护后用3倍树脂体积的DMF洗涤四次,然后抽干。
4.取少量树脂用茚三酮(九井水合茚三酮)法检测(检A、检B各两滴,100℃反应1min),树脂有颜色,说明脱保护成功。
5.称取氨基酸Ser适量和1-羟基-苯并并三唑(HOBT)适量于50ml的离心管中,加入20ml的DMF将其溶解,然后加入3ml的N,N二异丙基碳二亚胺(DIC)振荡摇匀1min,待溶液澄清后加入到反应器中,然后将反应器置于30℃的摇床中反应。
6.2小时后,用一定量的醋酸酐封头(醋酸酐:DIEA:DCM=1:1:2,v:v:v)半小时,然后用3倍树脂体积的DMF洗涤四次,抽干待用。
7.向反应器中加入一定量的20%哌啶(哌啶/DMF=1:4,v:v),放在脱色摇床上摇晃20min,以此来脱去树脂上的Fmoc保护基团。脱完保护后用DMF洗涤四次,然后抽干。
8.取少量树脂用茚三酮(九井水合茚三酮)法检测(检A、检B各两滴,100℃反应1min),树脂有颜色,说明脱保护成功。
9.称取后面第二个氨基酸适量和HOBT适量于50ml的离心管中,加入25ml的DMF将其溶解,然后加入2.5ml的DIC振荡摇匀1min,待溶液澄清后加入到反应器中,然后将反应器置于30℃的摇床中反应。
10.1小时后,取少量树脂检测,用茚三酮法检测(检A、检B各两滴,100℃反应1min),若树脂为无色,说明反应完全;若树脂有颜色,说明缩合不完全,继续反应。
11.待反应完全后,用DMF洗涤树脂四次,然后抽干,向反应器中加入一定量的20%哌啶(哌啶/DMF=1:4,v:v),放在脱色摇床上摇晃20min,以此来脱去树脂上的Fmoc保护基团。脱完保护后用DMF洗涤四次,然后抽干检测保护是否脱去。
12.按照步骤9-11依次接上氨基酸Ser、Gly、Ser、Ala、Ala、Trp、Asp、Asp、Ser、Ala、Gly、Gly、Ala、Gly、Gly、Gln、Gly、Leu、Arg、Val、Thr、Ala、Leu。
13.待接上最后一个氨基酸后,脱去保护,用DMF洗涤四次,然后用甲醇将树脂抽干。然后用95切割液(三氟乙酸:1,2乙二硫醇:3,异丙基硅烷:水=95:2:2:1,v:v:v)将生物活性肽从树脂上切割下来(每克树脂加10ml切割液),并用冰乙醚(切割液:乙醚=1:9,v:v)离心沉降四次。
至此,人工合成了生物活性肽SGSAAWDDSAGGAGGQGLRVTAL。
二、生物活性肽的确认
1)UPLC分析
UPLC条件如下:
仪器:Waters ACQUITY UPLC超高效液相、电喷雾、四级杆、飞行时间质谱仪
色谱柱规格:BEH C18色谱柱
流速:0.4mL/min
温度:50℃
紫外检测波长:210nm
进样量:2μL
梯度条件:A液:含有0.1%甲酸(v/v)的水,B液:含有0.1%甲酸(v/v)的乙腈
2)质谱分析
质谱条件如下:
离子方式:ES+
质量范围(m/z):100、1000
毛细管电压(Capillary)(kV):3.0
采样锥(V):35.0
离子源温度(℃):115
去溶剂温度(℃):350
去溶剂气流(L/hr):700.0
碰撞能量(eV):4.0
扫描时间(sec):0.25
内扫描时间(sec):0.02
根据以上分析方法,利用超高效液相、电喷雾、四级杆、飞行时间质谱,对生物活性肽SGSAAWDDSAGGAGGQGLRVTAL进行色谱分析和质谱分析。生物活性肽SGSAAWDDSAGGAGGQGLRVTAL一级质谱图如图1所示,提取峰的二级质谱图和az、by断裂情况如图2所示,可得此峰的生物活性肽质荷比为1052.512,保留时间是46.22min。
3)结果
由图2可知,根据az、by断裂的情况,经过Mascot软件分析计算,得到质荷比1052.512的片段序列为Ser、Gly、Ser、Ala、Ala、Trp、Asp、Asp、Ser、Ala、Gly、Gly、Ala、Gly、Gly、Gln、Gly、Leu、Arg、Val、Thr、Ala、Leu(SGSAAWDDSAGGAGGQGLRVTAL),记为SEQ ID NO:1。该片段与Protein tyrosine phosphatase receptor type C-associated蛋白第175~197位的残基序列相对应,序列见SEQ ID NO:2。
实施例2生物活性肽的免疫活性实验
一、生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的促巨噬细胞吞噬中性红能力实验
1.实验试剂及仪器:
试剂:实验动物balb/c小鼠(雄性6-8周龄)上海交通大学农业与生物学院动物实验中心;实施例1获得的小鼠脾脏淋巴细胞来源生物活性肽SGSAAWDDSAGGAGGQGLRVTAL;LPS,购自Sigma公司;中性红染色液,碧云天生物技术研究所生产。
仪器设备:LRH-250F生化培养箱上海恒科技有限公司;GL-22M高速冷冻离心机上海卢湘仪离心机仪器有限公司;Hera cell 150 CO2培养箱Heraeus公司;Dragon WellscanMK3酶标仪Labsystems公司。
2.实验方法:
加入细胞个数为2×106/ml的细胞悬液100μl/孔,贴壁纯化后加入含活性肽SGSAAWDDSAGGAGGQGLRVTAL(0.2mg/ml)的RPMI1640完全培养液(10%FBS)200μl/孔为实验组,添加不含活性肽的RPMI1640完全培养液(10%FBS)200μl/孔进行培养的设为空白组;并且实验组和空白组在培养到24h时加入LPS至终浓度10μg/ml;继续培养至48h后,吸弃细胞培养液。PBS清洗孔底后加入37℃的中性红染液80μl/孔,10分钟后吸弃染液,用PBS清洗两次后,每孔加入150μl细胞裂解液(冰醋酸:无水乙醇=1:1,v/v)。4℃隔夜溶解后,在波长540nm下测定吸光度值(OD540)。
3.实验结果及分析:
表1生物活性肽SGSAAWDDSAGGAGGQGLRVTAL促巨噬细胞吞噬中性红能力的测定
实验分组 | 吸光度值(OD540) |
空白组 | 0.07582±0.0583 |
实验组(0.2mg/ml) | 0.2013±0.0482** |
注:*,与阴性对照比较,有显著性差异(P<0.05)
**,与阴性对照组比较,有极显著性差异(P<0.01)
实验结果见表1,与细胞空白相比较,添加0.2mg/ml生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的炎症组巨噬细胞吞噬中性红能力明显增加,而且与细胞空白组比较,具有极显著性差异(P<0.01)。说明生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在有炎症发生的情况下对体外巨噬细胞吞噬中性红能力具有显著的促进作用。
二、生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的促巨噬细胞分泌细胞因子的实验(ELISA法)
1.实验试剂及仪器:
试剂:实验动物balb/c小鼠(雄性6、8周龄),上海斯莱克实验动物有限公司;小鼠淋巴细胞提取液,上海索莱宝生物科技有限公司;RPMI1640培养基,GIBCO公司;牛血清白蛋白(bovine serum albumin,BSA),Genebase公司;实施例1获得的小鼠脾脏淋巴细胞来源性生物活性肽SGSAAWDDSAGGAGGQGLRVTAL;ELISA细胞因子快速试剂盒(TNF-α和IL-6),武汉博士德生物工程有限公司。
仪器设备:LRH、250F生化培养箱上海恒科技有限公司;GL、22M高速冷冻离心机上海卢湘仪离心机仪器有限公司;Hera cell 150 CO2培养箱Heraeus公司;Dragon WellscanMK3酶标仪Labsystems公司。
2.实验方法:
加入细胞个数为2×106/ml的细胞悬液100μl/孔,贴壁纯化后加入含肽的RPMI1640完全培养液(10%FBS)200μl/孔,炎症组在24小时时加入LPS至终浓度10μg/ml,连续培养48小时,炎症组在培养终止前24小时加入LPS至终浓度100ng/ml。培养终止后,离心收集细胞培养液上清液。在已包被细胞因子抗体的酶标板中加入100μl上清液,37℃反应90分钟后,加入生物素标记抗体,37℃反应60分钟,PBS洗涤后,加入亲和素、过氧化物酶复合物,反应30分钟。PBS洗涤后加入显色液,反应20分钟。加入显色终止液后,使用酶标仪在波长450nm下测定吸光度值(OD450)。
3.实验结果及分析:
表2生物活性肽SGSAAWDDSAGGAGGQGLRVTAL对巨噬细胞细胞因子水平影响的测定
注:*,与阴性对照比较,有显著性差异(P<0.05);**,与阴性对照组比较,有极显著性差异(P<0.01)
从表2中可知,在TNF-α和IL-6这两种细胞因子的实验结果中,TNF-α和IL-6在0.2mg/ml及以上均出现了极显著性差异(P<0.01),证明了一定浓度下的SGSAAWDDSAGGAGGQGLRVTAL可促进小鼠腹腔巨噬细胞活化并释放TNF-α和IL-6,TNF-α、IL-6是促炎因子,能诱导B细胞分化和产生抗体,并诱导T细胞活化增殖、分化,参与机体的免疫应答。因此,一定浓度下的SGSAAWDDSAGGAGGQGLRVTAL提高这些细胞因子在正常巨噬细胞静息状态下的作用,从而调节机体的免疫力。
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。
序列表
<110> 上海交通大学,浙江辉肽生命健康科技有限公司
<120> 一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL及其制备方法和应用
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 23
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ser Gly Ser Ala Ala Trp Asp Asp Ser Ala Gly Gly Ala Gly Gly Gln
1 5 10 15
Gly Leu Arg Val Thr Ala Leu
20
<210> 2
<211> 197
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Ala Leu Pro Gly Thr Leu Arg Phe Gly Val Leu Met Ala Leu Pro
1 5 10 15
Gly Ala Leu Ala Ser Gly Ala Asp Pro Glu Asp Gly Val Gly Ser Ser
20 25 30
Val Val Thr Ile Val Leu Leu Leu Leu Leu Leu Leu Leu Leu Val Thr
35 40 45
Ala Leu Ala Leu Ala Trp Arg Arg Leu Ser His Ala Ser Gly Gly Tyr
50 55 60
Tyr His Pro Ala Arg Leu Gly Ala Ala Leu Trp Gly His Thr Cys Arg
65 70 75 80
Leu Leu Trp Ala Ser Pro Ala Gly Arg Trp Leu Arg Ala Arg Thr Glu
85 90 95
Leu Glu Ser Pro Glu Glu Ser Gly Pro Pro Glu Asp Glu Glu Asp Ala
100 105 110
Glu Asp Phe Val Ile Asp Gly Gly Pro Glu Glu Ala Ala Ala Lys Glu
115 120 125
Glu Glu Gln Arg Cys Gln Ala Glu Gln Thr Arg Asp Pro Arg Asp Thr
130 135 140
Asp Ser Asp Gly Gly Leu Gly Leu Ser Ser Gln Gly Pro Val Gly Ser
145 150 155 160
Gly Ser Ser Ala Glu Ala Leu Leu Ser Asp Leu His Ala Phe Ser Gly
165 170 175
Ser Ala Ala Trp Asp Asp Ser Ala Gly Gly Ala Gly Gly Gln Gly Leu
180 185 190
Arg Val Thr Ala Leu
195
Claims (10)
1.一种生物活性肽SGSAAWDDSAGGAGGQGLRVTAL,其特征在于,其氨基酸序列为Ser-Gly-Ser-Ala-Ala-Trp-Asp-Asp-Ser-Ala-Gly-Gly-Ala-Gly-Gly-Gln-Gly-Leu-Arg-Val-Thr-Ala-Leu。
2.编码权利要求书1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的多核苷酸。
3.如权利要求1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的制备方法,其特征在于,通过基因工程的方法人工合成,或从细胞中通过分离纯化的方法直接获得,或直接通过化学合成制备。
4.如权利要求1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的应用,其特征在于,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备具有抗炎功能的药物或化妆品中的应用。
5.如权利要求4所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的应用,其特征在于,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备有炎症发生的情况下对体外巨噬细胞吞噬中性红能力促进的药物中的应用。
6.如权利要求1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的应用,其特征在于,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备具有免疫调节功能的食物或药物中的应用。
7.根据权利要求6所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的应用,其特征在于,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL在制备促进巨噬细胞活化并释放细胞因子的食物或药物中的应用。
8.一种抗炎产品,其特征在于,包括如权利要求1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL或所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物;所述的抗炎产品包括抗炎药物或抗炎化妆品;所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物是指具有与所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL相同的活性或更优的活性。
9.一种具有免疫调节功能的产品,其特征在于,包括如权利要求1所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL或所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物;所述具有免疫调节功能的产品包括具有免疫调节功能的食品或具有免疫调节功能的药物;所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物是指具有与所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL相同的活性或更优的活性。
10.根据权利要求8所述一种抗炎产品或权利要求9所述一种具有免疫调节功能的产品,其特征在于,所述生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的衍生物,是指在生物活性肽SGSAAWDDSAGGAGGQGLRVTAL的氨基酸侧链基团上、氨基端或羧基端进行羟基化、羧基化、羰基化、甲基化、乙酰化、磷酸化、酯化或糖基化修饰,得到的生物活性肽衍生物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011468803.1A CN112480235B (zh) | 2020-12-14 | 2020-12-14 | 一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011468803.1A CN112480235B (zh) | 2020-12-14 | 2020-12-14 | 一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112480235A true CN112480235A (zh) | 2021-03-12 |
CN112480235B CN112480235B (zh) | 2022-07-15 |
Family
ID=74916786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011468803.1A Active CN112480235B (zh) | 2020-12-14 | 2020-12-14 | 一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112480235B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052182A2 (en) * | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
CN104694448A (zh) * | 2013-12-06 | 2015-06-10 | 清华大学 | 一种生产紫色杆菌素的工程菌及其应用 |
CN104998261A (zh) * | 2015-08-12 | 2015-10-28 | 金陵科技学院 | 一种双重载药的荧光磁性微球复合体系及其制备方法 |
CN108473990A (zh) * | 2016-10-27 | 2018-08-31 | 中国科学院微生物研究所 | 氨基酸衰减子的改造方法及其在生产中的应用 |
WO2018209127A1 (en) * | 2017-05-11 | 2018-11-15 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Antimicrobial peptides with alpha-core helices |
CN110938130A (zh) * | 2019-11-08 | 2020-03-31 | 上海交通大学 | 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用 |
CN112812168A (zh) * | 2021-01-19 | 2021-05-18 | 浙江辉肽生命健康科技有限公司 | 一种生物活性肽glnmcrqcf及其制备方法和应用 |
-
2020
- 2020-12-14 CN CN202011468803.1A patent/CN112480235B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005052182A2 (en) * | 2003-11-26 | 2005-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method of analyzing plasma membrane protein content of cells |
CN104694448A (zh) * | 2013-12-06 | 2015-06-10 | 清华大学 | 一种生产紫色杆菌素的工程菌及其应用 |
CN104998261A (zh) * | 2015-08-12 | 2015-10-28 | 金陵科技学院 | 一种双重载药的荧光磁性微球复合体系及其制备方法 |
CN108473990A (zh) * | 2016-10-27 | 2018-08-31 | 中国科学院微生物研究所 | 氨基酸衰减子的改造方法及其在生产中的应用 |
WO2018209127A1 (en) * | 2017-05-11 | 2018-11-15 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Antimicrobial peptides with alpha-core helices |
CN110938130A (zh) * | 2019-11-08 | 2020-03-31 | 上海交通大学 | 一种生物活性多肽rvfqplphenkpltl及其制备方法和应用 |
CN112812168A (zh) * | 2021-01-19 | 2021-05-18 | 浙江辉肽生命健康科技有限公司 | 一种生物活性肽glnmcrqcf及其制备方法和应用 |
Non-Patent Citations (6)
Title |
---|
ARTHUR KWOK LEUNG CHEUNG 等: "Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma", 《CANCER RES》 * |
GENBANK: "protein tyrosine phosphatase receptor type C-associated protein precursor [Mus musculus]", 《GENBANK》 * |
UNIPROTKB: "UniProtKB-Q64697 (PTCA_MOUSE)", 《UNIPROTKB》 * |
梁宋平: "《生物化学与分子生物学实验教程》", 31 March 2003, 高等教育出版社 * |
胡龙: "黄连素抑制单核/巨噬细胞TNF-α、Il-6、Il-1β的表达", 《万方数据》 * |
董启超 等: "脾多肽对幽门螺旋杆菌脂多糖诱导RAW264.7巨噬细胞TNF-α、IL-1β、IL-6及IL-17的作用", 《海南医学》 * |
Also Published As
Publication number | Publication date |
---|---|
CN112480235B (zh) | 2022-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112759636B (zh) | 具有氨基酸结构eslkgvdpkflr的生物活性肽及其制备方法和应用 | |
CN112812168A (zh) | 一种生物活性肽glnmcrqcf及其制备方法和应用 | |
CN112625113B (zh) | 一种生物活性肽agydveknnsriklglk及其制备方法和应用 | |
CN112745380B (zh) | 具有氨基酸结构raglqfpvgrvh的生物活性肽及其制备方法和应用 | |
CN112501140A (zh) | 一种生物活性多肽yfgsgfaapffivrhqllkk及其制备方法和应用 | |
CN112646022A (zh) | 一种生物活性肽pkcpkcdkevyfaerv及其制备方法和应用 | |
CN112724237B (zh) | 一种生物活性肽ggsdgygsgrgf及其制备方法和应用 | |
CN112480234B (zh) | 一种生物活性肽aaggydveknnsriklglk及其制备方法和应用 | |
CN112500467B (zh) | 一种生物活性肽rrecpsdecgagvf及其制备方法和应用 | |
CN112500468B (zh) | 一种生物活性肽rlafiahpklg及其制备方法和应用 | |
CN112661830B (zh) | 具有氨基酸结构airndeelnkllgr的生物活性肽及其制备方法和应用 | |
CN112500469B (zh) | 一种生物活性多肽aapaapaaappae及其制备方法和应用 | |
CN112480233A (zh) | 一种生物活性肽iahpklgkrir及其制备方法和应用 | |
CN112592396A (zh) | 一种生物活性肽vdpfskkdw及其制备方法和应用 | |
CN112480232A (zh) | 一种生物活性肽vsladlqndevafr及其制备方法和应用 | |
CN112745379A (zh) | 具有氨基酸结构rdnkktriipr的生物活性肽及其制备方法和应用 | |
CN112625112A (zh) | 一种生物活性多肽paapaqlpkki及其制备方法和应用 | |
CN112724238B (zh) | 具有氨基酸结构fregttpkpk的生物活性肽及其制备方法和应用 | |
CN112759634B (zh) | 具有氨基酸结构feyieenky的生物活性肽及其制备方法和应用 | |
CN112724239B (zh) | 具有氨基酸结构nkeldpvqklfvdkireyk的生物活性肽及其应用 | |
CN112480235A (zh) | 一种生物活性肽sgsaawddsaggaggqglrvtal及其制备方法和应用 | |
CN112812169B (zh) | 具有氨基酸结构apkiqrlvtpr的生物活性肽及其制备方法和应用 | |
CN112778410B (zh) | 一种生物活性肽saprhgslgflprk及其制备方法和应用 | |
CN112812170B (zh) | 具有氨基酸结构llpkkte的生物活性多肽及其制备方法和应用 | |
CN112812171B (zh) | 具有氨基酸结构vvrkplnkegkkp的生物活性肽及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |